The auxiliary spliceosomal protein SCNM1 contributes to recognition of nonconsensus splice donor sites. SCNM1 was first identified as a modifier of the severity of a sodium channelopathy in the mouse. The most severely affected strain, C57BL/6J, carries the variant allele SCNM1
INTRODUCTION
Scnm1 (sodium channel modifier 1) is an auxiliary splice factor that was identified by its role in the strain-specific lethality of the sodium channel mutation Scn8a medJ (BUCHNER et al. 2003) . A direct role for SCNM1 in splicing the Scn8a medJ transcript was subsequently demonstrated in a cell culture assay (HOWELL et al. 2007 ). The Scn8a medJ mutation is a 4 bp deletion in the splice donor site of exon 3, nucleotides +5 to +8, generating a weak site with a C nucleotide at the consensus +5G position (KOHRMAN et al. 1996) . In the presence of a wildtype Scnm1 gene, only 10% of Scn8a medJ transcripts are correctly spliced and encode active channel, while ~90% of the transcripts skip exon 2 and exon 3. In the presence of the C57BL/6J-specific
Scnm1
R187X allele, the amount of full length transcript is reduced to 5% and the Scn8a medJ mice do not survive (BUCHNER et al. 2003) . It is not clear from the earlier studies whether Scnm1 R187X is a null allele or retains partial function.
SCNM1 is a 229 amino acid protein with a bipartite nuclear localization signal near the N-terminus and one C2H2 zinc finger of the U1C type (Fig. 1A) . It is an accessory component of the U1-splicesome protein complex and interacts with the spliceosomal Sm and U1-70K
proteins (HOWELL et al. 2007) . Along with other members of the U1C protein family SCNM1 is thought to contribute to the recognition of different subsets of non-consensus splice donor sites Auxiliary splice factors can be used to restore the activity of genes with splice site mutations. For example, in cells from a cystic fibrosis patient with an intronic mutation that generates a cryptic splice donor site, overexpression of Htra2-β1 increased the level of correctly spliced transcript and restored CFTR function (NISSIM-RAFINIA et al. 2004 ).
Inactivation of a splice factor may itself lead to disease. Germline inactivation of the SR proteins ASF/SF2, SC35 and SRp20 results in embryonic lethality (XU et al. 2005) . The neuron specific auxiliary splice factor NOVA-1 and its paralog NOVA-2 regulate alternative splicing of 41 synapse-related transcripts (ULE et al. 2006) . Loss of NOVA-1 due to auto-immune disease in cancer patients leads to ataxia, seizures and dementia. Inactivation of mouse NOVA-1 is lethal, but inactivation of NOVA-2 is not (HUANG et al. 2005) . Patients with mutations in the splice factors PRPF31, PRPF8 and PRPF3 develop photoreceptor degeneration, although the proteins are ubiquitously expressed. They are associated with the spliceosomal complex U4/U6.U5 trisnRNP that is involved in the activation of the spliceosome for lariat formation and intron removal (PACIONE et al. 2003) . Mutation of PRPF31 inhibits pre-mRNA splicing of Rhodopsin leading to retinal apoptosis and autosomal dominant retinitis pigmentosa (YUAN et al. 2005) .
To further characterize the function of SCNM1, we examined two new alleles, an internal deletion of 92 residues generated by gene targeting in ES cells (Fig. 1A) and an ENU-induced missense mutation identified by screening a DNA repository (MICHAUD et al. 2005) . We examined the effect of the deletion allele using expression arrays, and examined the role of Scnm1 R187X in the strain-specific lethality of two mouse mutants.
MATERIALS AND METHODS

Generation of a floxed allele of Scnm1
The targeted allele of Scnm1 was constructed as shown in Figure 1 . Two genomic fragments (5.0 kb and 4.4 kb) containing Scnm1 and flanking regions were amplified from the -6 -C57BL/6J BAC clone RP23-11G21 (http://bacpac.chori.org) and cloned into pSP72 (Promega , which generated a 1.8 kb PCR product after correct integration ( Fig 1C) . The 3` region was evaluated by southern blot hybridization of BamHI digested DNA using probe HP2 to detect a wildtype product of 8.5 kb and a targeted product of 10.4 kb (Fig 1D) .
Two euploid clones were expanded, microinjected into albino C57BL/6J-Tyr
c-2J
blastocysts, and implanted into pseudo-pregnant C57BL/6J females. Male chimeric founders with patches of white hair were mated with C57BL/6J females. Germline transmission of the targeted allele was detected by PCR of genomic DNA using primers 3 and 2 flanking the first loxP site (Fig. 1B) , generating a 187 bp wildtype product and a 220 bp product from the targeted allele. FRT sites were removed in vivo by crossing male Scnm1 TAR /+ mice with a strain expressing the FLPE recombinase [B6:SJL-Tg(ACTFLPe)9205Dym/J, Jackson Laboratory stock 003800]. The floxed allele was detected by PCR using primers 4 and 5 flanking the second loxP site (Fig. 1B) , which generated a 220 bp wildtype product and a 305 bp floxed allele product. et al. 1996) .
Generation of the Scnm1
The deleted allele (Δ3-5) was detected by PCR using primers 2, 3 and 5 ( Fig 1B) . Five micrograms of total RNA was treated with DNase 1 (Invitrogen Corporation) and reverse-transcribed in a 20 uL reaction using the SuperScript FirstStrand Synthesis System (Invitrogen Corporation) according to the manufacturer's protocol.
Correctly spliced Scn8a transcripts were specifically amplified with a forward primer in exon 1 (5` CCG ACA GTT TCA AGC CTT TCA CCC 3`) and a reverse primer in exon 2 (5` AGG ACT TAG AAT GTA CAA GGC AGG 3`). Only correctly spliced Scn8a transcripts are amplified with these primers as the exon 3 splice site mutation in Scn8a medJ results in a majority of incorrectly spliced transcripts lacking exon 2 and exon 3 (KOHRMAN et al. 1996) . RT-PCR products were examined on agarose gels.
To quantitate the correctly spliced Scn8a transcript in each cDNA we used the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Reactions were carried out in a 96 well plate (Applied Biosystems) with a final reaction volume of 30 uL. 
Protein interaction and yeast two-hybrid screen
The yeast two-hybrid screen of a mouse embryo cDNA library was carried out as previously 
RESULTS
Targeted disruption of Scnm1
In order to generate a targeted allele on a homogenous C57BL/6J background for subsequent phenotypic analysis, targeting was carried out in ES cell line BL/6-III, and the targeting construct was derived from a C57BL/6J BAC clone. To avoid disrupting the expression of the nearby upstream and downstream genes in this gene rich region, we introduced the loxP sites into intron 2 and intron 5 of Scnm1 (Fig. 1B ). This produced a target for CRE recombinase that results in removal of most of the coding sequence of SCNM1 ( Figure 1A ). Correct targeting of ES cells was detected by PCR for the 5' flank ( Figure 1C ) and by Southern blotting for the 3' flank ( Figure 1D ). Germline transmission of the targeted construct was obtained from two chimeric founders derived from the same ES-cell clone. The PGK-neo cassette was removed by crossing male Scnm1 TAR/+ mice with an FLPE transgenic mouse to generate the Scnm1 flox allele (Fig. 1B) .
Floxed mice were crossed with an EIIa-CRE transgenic line expressing Cre recombinase in the zygote (LAKSO et al. 1996) . Chimeric offspring were intercrossed to obtain mice with germline deletion of exons 3-5 of Scnm1, which were identified by genotyping as shown in Figure 1E .
Phenotype of Scnm1
Δ 3-5 mice with ubiquitous deletion of exons 3-5
Normal Mendelian inheritance was observed in crosses between Scnm1 . Other examples of CRE transgenes that cause reduced body weight were recently described (NAICHE and PAPAIOANNOU 2007) . Homozygous Scnm1 were detected in mice after aging beyond one year (data not shown).
Western blots from Scnm1
Δ 3-5 homozygotes demonstrated that the mutant protein is stable in vivo, but is present at reduced levels (Fig. 1F) . The mutant protein migrates more slowly than predicted by its 10.3 kDa calculated molecular weight as previously reported for other SCNM1
isoforms (HOWELL et al. 2007 ). Immunohistochemistry of cultured fibroblasts from Scnm1
homozygotes demonstrated that the mutant protein, which retains the nuclear localization signal (Fig. 1A) , is correctly localized to the nucleus (Fig. 1G) .
Viability of Scnm1
Δ 3-5 homozygotes on other strain backgrounds Δ 3-5/+ mice were crossed to strains 129S6 and C3H, and homozygous F2 mice were generated. In both crosses, homozygotes were born in the predicted Mendelian ratios (Table 1) , and no abnormal phenotypes were observed. Figure 2A ). The data demonstrate that the Scnm1 (Table 3 ).
The eight double homozygotes all developed hind limb paralysis that was not observed in littermates who were compound heterozygotes or homozygotes for Scnm1 R187X (Table 3 and Figure 2B ). These data demonstrate that the residual 1.4% of full-length Scn8a transcripts in
Scn8a medJ/medJ
,Scnm1 Δ3-5/Δ3-5 mice is insufficient for normal hind limb innervation, and confirms the greater severity of the Δ 3-5 allele. The relationship between hind limb phenotype and transcript level is summarized in Figure 2C .
Expression array analysis of Scnm1
Δ 3-5 tissues.
To identify additional transcripts with altered expression caused by the Scnm1 transcript. Decreased transcript abundance was confirmed by RT-PCR (data not shown), and is likely to contribute to the reduced amount of mutant protein (Fig 1F) . The 20 genes with largest changes are listed in Table 4 ; they include eight with nucleic acid binding domains and two splice factors. In view of the small magnitude of the observed changes, confirmation of biological significance would require further study.
To determine whether the Scnm1 It thus appears that reduced expression of Scnm1 alone does not produce major changes in transcript processing.
Can SCNM1 rescue defective splicing of a Brunol4 null allele?
The spontaneous neurological mutant frequent-flyer (Ff) was caused by a transgene insertion in intron 1 of Bruno-like 4 (Brunol4), which encodes an RNA binding protein involved in RNA processing. There is no detectable Brunol4 transcript in frequent-flyer homozygous mice, apparently due to disrupted splicing by the inserted transgene (YANG et al. 2007 ).
Brunol4
Ff homozygotes are not viable on strain C57BL/6J but have higher rates of survival on other inbred strains (YANG et al. 2007 ). To determine whether impaired splicing by the Scnm1 R187X allele accounts for the greater lethality on C57BL/6J, we generated B6.Brunol4 Figure 3A ). Cysteine-rich domains are known to interact with C2H2 zinc finger domains (CHEN et al. 1996; MIZUGISHI et al. 2004) . To verify the interaction between SCNM1 and I-MFA, we co-transfected COS7 cells with full-length cDNAs for myc-tagged I-MFA and SCNM1. The two proteins were co-precipitated from the COS7 cell extracts by anti-SCNM1 and by anti-myc antisera ( Figure 3B, 3C ). The interaction with I-MFA suggests that SCNM1 might have a second role in transcriptional regulation.
To test the biological significance of this interaction, we tested the ability of wildtype Scnm1 to rescue a targeted null allele of I-MFA, which exhibits embryonic lethality on strain
We screened stored, mutagenized genomic DNA from the Cryopreserved Mutant Mouse Bank at the Oak Ridge National Laboratory, in order to identify new variants of SCNM1. DNA was analysed by heteroduplex analysis as previously described (MICHAUD et al. 2005) . The nonsynonymous variants I112T, S167S, and L228S, and the intron substitution IVS5+62T>C, were identified in genomic DNA from mutagenized mice. We selected I112T for in vivo analysis because of the evolutionary conservation of residue isoleucine 112. Sperm carrying this mutation were thawed and used for in vitro fertilization by intracytoplasmic sperm injection.
Heterozygous Scnm1 I112T mice were recovered and intercrossed to generate I112T homozygotes, which were viable and fertile. We then generated Scnm1 I112T/I112T ,Scn8a medJ/medJ double homozygotes. These mice did not survive beyond weaning, but they did not exhibit the hind limb paralysis described above for Scnm1
. Thus, I112T does not reduce SCNM1 function as severely as Scnm1
.
DISCUSSION
Analysis of an allele series can often provide additional insights into gene function beyond that available from a single allele (OLIVER et al. 2007 and neurofibromatosis type 2 (NF2) (FRUCHT et al. 2001; GURVICH et al. 2008; KLUWE et al. 1998; MOHAMED et al. 2003; ROSSENBACKER et al. 2005) . There is evidence that the clinical severity of these disorders is influenced by splicing efficiency. Therapeutic strategies that target the correction of splicing defects are under development for spinal muscular atrophy, familial dysautonomia, and cystic fibrosis (HIMS et al. 2007; HUA et al. 2008; NISSIM-RAFINIA et al. 2004 ). The molecular basis for individual variation in splicing efficiency is largely unknown, but identification of the responsible factors could facilitate the development of therapies. The Scn8a medJ mutant utilized in our work is a sensitive reporter for splicing of nonconsensus splice donor sites, since a two-fold decrease in splicing results in a visible change in phenotype.
Scn8a
medJ could be used for in vivo discovery of splicing modifier genes, or testing small molecule therapeutics for splicing deficiencies.
In conclusion, we have generated a new, severe allele for dissection of the splicing function of SCNM1 and the mechanism of splice donor site choice. Future work will focus on combining this allele with mutations of other accessory splice factors. Cultured cells from Scnm1 (-ΔΔCt) x 100, mean ± SD (n), where n = number of replicate assays (4 per mouse). *, (KEARNEY et al. 2002); †, (BUCHNER et al. 2003) . n.a., not applicable. immunoprecipitate contains MYC/I-MFA, but the pre-immune rabbit serum does not.
Genotyping of Scnm1
